# Evaluate Safety, Tolerability, PK of TBAJ-876 in Healthy Adults

> **NCT04493671** · PHASE1 · COMPLETED · sponsor: **Global Alliance for TB Drug Development** · enrollment: 137 (actual)

## Conditions studied

- Pulmonary Disease
- Tuberculosis, Pulmonary
- Tuberculosis
- Multi Drug Resistant Tuberculosis
- Drug Sensitive Tuberculosis
- Drug-resistant Tuberculosis
- Mycobacterium Tuberculosis Infection

## Interventions

- **DRUG:** TBAJ-876 suspension
- **DRUG:** Placebo suspension
- **DRUG:** TBAJ-876 100 mg tablet
- **DRUG:** TBAJ-876 25 mg tablet

## Key facts

- **NCT ID:** NCT04493671
- **Lead sponsor:** Global Alliance for TB Drug Development
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-08
- **Primary completion:** 2022-06-16
- **Final completion:** 2022-11-15
- **Target enrollment:** 137 (ACTUAL)
- **Last updated:** 2025-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04493671

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04493671, "Evaluate Safety, Tolerability, PK of TBAJ-876 in Healthy Adults". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04493671. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*